SCHEMBL2127752

SCHEMBL2127752

COC(=O)c1ccc2nc(-c3ccc(C)cc3)cn2c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.75
NPC1 O15118 11/20 0.75
RAB9A P51151 11/20 0.75
KDM4E B2RXH2 9/20 0.75
GLA P06280 1/20 0.75
ALDH1A3 P47895 5/20 0.70
MAPT P10636 3/20 0.66
KMT2A Q03164 4/20 0.65
SMN1; SMN2 Q16637 6/20 0.60
MEN1 O00255 2/20 0.60
PAX8 Q06710 2/20 0.60
MITF O75030 1/20 0.60
KDM5A P29375 1/20 0.60
KDM5C P41229 1/20 0.60
POLB P06746 3/20 0.60
GAA P10253 3/20 0.60
HPGD P15428 3/20 0.56
LMNA P02545 2/20 0.56
HSP90AA1 P07900 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2310649 0.92 ALDH1A1 (0.74) ALDH1A1NPC1RAB9AKDM4EGLA
SCHEMBL2127209 0.89 NPC1 (0.76) ALDH1A1NPC1RAB9AKDM4EGLA
SCHEMBL2127079 0.89 NPC1 (0.74) ALDH1A1NPC1RAB9AKDM4EGLA
SCHEMBL2127115 0.89 ALDH1A1 (0.88) ALDH1A1NPC1RAB9AKDM4EGLA
SCHEMBL2126735 0.89 NPC1 (0.72) ALDH1A1NPC1RAB9AKDM4EGLA
SCHEMBL2128899 0.89 ALDH1A1 (0.72) ALDH1A1NPC1RAB9AKDM4EGLA
SCHEMBL2127861 0.89 ALDH1A1 (0.72) ALDH1A1NPC1RAB9AKDM4EGLA
SCHEMBL407421 0.89 ALDH1A1 (0.83) ALDH1A1NPC1RAB9AKDM4EGLA
Bromide SCHEMBL1691882 0.88 NPC1 (0.70) ALDH1A1NPC1RAB9AKDM4EGLA
Bromide SCHEMBL1691775 0.88 ALDH1A1 (0.70) ALDH1A1NPC1RAB9AKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US claimed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP claimed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US claimed
EP-2129375-A1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-12-09 EP claimed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO claimed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP claimed
WO-2023236820-A1 AROMATIC SIX-MEMBERED RING-FUSED IMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 沈阳药科大学 2023-12-14 WO disclosed
CN-112538087-B Synthesis method of imidazopyridine compound 温州大学新材料与产业技术研究院 2021-10-15 CN disclosed
EP-2353613-B1 Zolpidem immunoassay with extended detection window RANDOX LAB LTD (GB) 2014-07-30 EP disclosed
EP-2353613-B1 Zolpidem immunoassay with extended detection window RANDOX LAB LTD (GB) 2014-07-30 EP disclosed
US-8673652-B2 Immunoassay with extended detection window RANDOX LABORATORIES LIMITED (IE) 2014-03-18 US disclosed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
EP-2129375-A1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-12-09 EP disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS NOS1, PTGIS, NOS2 ALDH1A1 1286/4885NPC1 2959/4885RAB9A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.